IBDEI3BX ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.4)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.4,2293,0)
 ;;=RETINA - VASCULAR^12^176
 ;;^UTILITY(U,$J,358.4,2294,0)
 ;;=EYELIDS / LASHES^2^176
 ;;^UTILITY(U,$J,358.4,2295,0)
 ;;=NEURO / STRABISMUS^18^176
 ;;^UTILITY(U,$J,358.4,2296,0)
 ;;=ORBIT - PLASTICS^20^176
 ;;^UTILITY(U,$J,358.4,2297,0)
 ;;=VITREOUS^17^176
 ;;^UTILITY(U,$J,358.4,2298,0)
 ;;=ORBIT - TRAUMA^19^176
 ;;^UTILITY(U,$J,358.4,2299,0)
 ;;=LACRIMAL / NLD / NEOPLASMS^3^176
 ;;^UTILITY(U,$J,358.4,2300,0)
 ;;=MOST FREQUENT^1^176
 ;;^UTILITY(U,$J,358.4,2301,0)
 ;;=CONJUNCTIVA / SCLERA^4^176
 ;;^UTILITY(U,$J,358.4,2302,0)
 ;;=CORNEA / ULCER^5^176
 ;;^UTILITY(U,$J,358.4,2303,0)
 ;;=LENS / CATARACT / POSTOP^6^176
 ;;^UTILITY(U,$J,358.4,2304,0)
 ;;=IRIS / UVEITIS^7^176
 ;;^UTILITY(U,$J,358.4,2305,0)
 ;;=GLAUCOMA - OPEN ANGLE^8^176
 ;;^UTILITY(U,$J,358.4,2306,0)
 ;;=GLAUCOMA - CLOSED ANGLE^9^176
 ;;^UTILITY(U,$J,358.4,2307,0)
 ;;=GLAUCOMA - SECONDARY^10^176
 ;;^UTILITY(U,$J,358.4,2308,0)
 ;;=RETINA - CHOROID / TUMORS / INFLAM^14^176
 ;;^UTILITY(U,$J,358.4,2309,0)
 ;;=RETINA - TEAR / PERIPH / DEGENERATION^15^176
 ;;^UTILITY(U,$J,358.4,2310,0)
 ;;=RETINA - MACULA^11^176
 ;;^UTILITY(U,$J,358.4,2311,0)
 ;;=SUICIDE IDEATIONS/ATTEMPTS^23^176
 ;;^UTILITY(U,$J,358.4,2312,0)
 ;;=PMH / OTHER^22^176
 ;;^UTILITY(U,$J,358.4,2313,0)
 ;;=RETINA - VEGF INJECT DX CODES^16^176
 ;;^UTILITY(U,$J,358.4,2314,0)
 ;;=RETINA - DIABETIC RETINOPATHY^13^176
 ;;^UTILITY(U,$J,358.4,2315,0)
 ;;=NEW PATIENT^2^177
 ;;^UTILITY(U,$J,358.4,2316,0)
 ;;=ESTABLISHED PATIENT^1^177
 ;;^UTILITY(U,$J,358.4,2317,0)
 ;;=CONSULTATIONS^3^177
 ;;^UTILITY(U,$J,358.4,2318,0)
 ;;=POST OP VISIT (GLOBAL)^4^177
 ;;^UTILITY(U,$J,358.4,2319,0)
 ;;=PENIS & SCROTUM^7^178
 ;;^UTILITY(U,$J,358.4,2320,0)
 ;;=URINARY TRACT DRAINAGE & IMAGING^9^178
 ;;^UTILITY(U,$J,358.4,2321,0)
 ;;=URODYNAMICS^10^178
 ;;^UTILITY(U,$J,358.4,2322,0)
 ;;=INJ & INTRAVESICAL MEDS^4^178
 ;;^UTILITY(U,$J,358.4,2323,0)
 ;;=CYSTOURETHROSCOPY^1^178
 ;;^UTILITY(U,$J,358.4,2324,0)
 ;;=PROSTATE BIOPSY & IMAGING^8^178
 ;;^UTILITY(U,$J,358.4,2325,0)
 ;;=NURSING PROCEDURES^6^178
 ;;^UTILITY(U,$J,358.4,2326,0)
 ;;=MISCELLANEOUS^5^178
 ;;^UTILITY(U,$J,358.4,2327,0)
 ;;=IMMUNIZATION ADMIN^2^178
 ;;^UTILITY(U,$J,358.4,2328,0)
 ;;=IMMUNIZATIONS^3^178
 ;;^UTILITY(U,$J,358.4,2329,0)
 ;;=BLADDER^4^179
 ;;^UTILITY(U,$J,358.4,2330,0)
 ;;=BENIGN NEOPLASIA-KIDNEY/URETER^2^179
 ;;^UTILITY(U,$J,358.4,2331,0)
 ;;=KIDNEY/URETER^6^179
 ;;^UTILITY(U,$J,358.4,2332,0)
 ;;=MALIGNANT NEOPLASMS^7^179
 ;;^UTILITY(U,$J,358.4,2333,0)
 ;;=COMPLICATIONS^5^179
 ;;^UTILITY(U,$J,358.4,2334,0)
 ;;=NEURO UROLOGY^8^179
 ;;^UTILITY(U,$J,358.4,2335,0)
 ;;=BENIGN NEOPLASM-PENIS^3^179
 ;;^UTILITY(U,$J,358.4,2336,0)
 ;;=SEXUAL DISORDERS^12^179
 ;;^UTILITY(U,$J,358.4,2337,0)
 ;;=PENIS^9^179
 ;;^UTILITY(U,$J,358.4,2338,0)
 ;;=POST OPERATIVE COMPLICATIONS^10^179
 ;;^UTILITY(U,$J,358.4,2339,0)
 ;;=PROSTATIC CONDITIONS^11^179
 ;;^UTILITY(U,$J,358.4,2340,0)
 ;;=TESTICULAR CONDITIONS^14^179
 ;;^UTILITY(U,$J,358.4,2341,0)
 ;;=URETHRA^16^179
 ;;^UTILITY(U,$J,358.4,2342,0)
 ;;=URINARY SYMPTOMS^16^179
 ;;^UTILITY(U,$J,358.4,2343,0)
 ;;=AFTERCARE POST SURGERY^1^179
 ;;^UTILITY(U,$J,358.4,2344,0)
 ;;=SUICIDAL IDEATIONS/ATTEMPTS^13^179
 ;;^UTILITY(U,$J,358.4,2345,0)
 ;;=PRE-OP VISIT^1^180
 ;;^UTILITY(U,$J,358.4,2346,0)
 ;;=CONSULTATION-CLINICIAN^2^180
 ;;^UTILITY(U,$J,358.4,2347,0)
 ;;=POST-OP VISIT^3^180
 ;;^UTILITY(U,$J,358.4,2348,0)
 ;;=A DIAGNOSIS^1^181
